Physician profile
Jessica Cuevas Rosas
NPI 1942809009
$23,316.13
in general payments reported to CMS, 2019-2025
42 companies · $2,944 in 2025
The $2,944 reported for 2025 was more than what 93% of Psychiatric/Mental Health (Clinical Nurse Specialist) providers received nationally (typical 2025 total: $244).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $4,752 · 2022: $4,688 · 2023: $6,039 · 2024: $4,894 · 2025: $2,944.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $14K · Education: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $13,765.04 |
| Education | $111.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,560.08 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $2,555.37 | 2021-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Teva Pharmaceuticals USA, INC. | $2,407.11 | 2021-2025 | Austedo Xr, Austedo, Uzedy |
| Otsuka America Pharmaceutical, INC. | $1,955.97 | 2021-2025 | Rexulti, Nuedexta, Abilify Asimtufii |
| Vanda Pharmaceuticals INC. | $1,655.23 | 2021-2025 | Fanapt, Hetlioz |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,422.43 | 2021-2025 | Caplyta |
| Neurocrine Biosciences, INC. | $1,249.53 | 2021-2025 | Ingrezza |
| Alkermes, INC. | $1,127.18 | 2021-2025 | Aristada, Lybalvi, Vivitrol |
| Supernus Pharmaceuticals, INC. | $1,051.80 | 2022-2024 | Qelbree, Qelbree |
| Lundbeck LLC | $917.52 | 2021-2025 | Rexulti, Brintellix |
| Indivior INC. | $579.36 | 2021-2025 | Sublocade, Perseris |
| Corium, LLC | $577.81 | 2022-2025 | Azstarys |
| Takeda Pharmaceuticals U.S.A., INC. | $523.01 | 2021-2024 | Trintellix |
| Sunovion Pharmaceuticals INC. | $519.60 | 2021-2022 | |
| Ironshore Pharmaceuticals INC. | $515.29 | 2022-2024 | Jornay Pm |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jessica Cuevas Rosas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.